Mankind Pharma Limited has entered into an exclusive in-licensing agreement with China-based Betta Pharmaceuticals for Ensartinib, a patented targeted therapy used in the treatment of certain forms of lung cancer. The agreement, announced on November 16, 2026, represents an expansion of Mankind Pharma’s oncology portfolio and its efforts to introduce specialised cancer treatments into the Indian pharmaceutical market.
Ensartinib is a targeted medicine approved by the United States Food and Drug Administration (US FDA) and China’s National Medical Products Administration (NMPA). The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an ALK inhibitor.
Under the agreement, Mankind Pharma will receive exclusive rights to develop, manufacture, register and commercialise Ensartinib in India, subject to the terms and conditions of the licensing arrangement. The partnership brings together Mankind Pharma’s domestic pharmaceutical capabilities and Betta Pharmaceuticals’ expertise in the development of innovative oncology medicines.
Exclusive Licensing Rights for the Indian Market
The agreement provides Mankind Pharma with exclusive licensing rights covering the development, manufacturing, regulatory registration and commercialisation of Ensartinib in India.
Under the financial terms of the arrangement, Mankind Pharma will make an upfront payment to Betta Pharmaceuticals, along with potential milestone payments linked to development and sales. The agreement also provides for royalty payments calculated on the annual net sales of Ensartinib in India.
The companies have not disclosed the financial value of the upfront payment, milestone commitments or royalty rates.
The licensing arrangement enables Mankind Pharma to undertake the necessary development, regulatory and commercial activities associated with introducing the medicine into the Indian market. However, the signing of the agreement does not constitute regulatory approval for Ensartinib in India.
The introduction of the medicine will remain subject to applicable Indian regulatory approvals and the completion of the necessary commercial and operational requirements.
Ensartinib Targets ALK-Positive Non-Small Cell Lung Cancer
Ensartinib belongs to a class of medicines known as anaplastic lymphoma kinase inhibitors. These drugs are designed to interfere with specific molecular mechanisms responsible for the growth and survival of certain cancer cells.
Non-small cell lung cancer accounts for the majority of lung cancer cases and includes several forms of the disease with different biological characteristics. In a proportion of patients, the cancer is associated with alterations involving the ALK gene, resulting in abnormal signalling that promotes tumour growth.
ALK-positive non-small cell lung cancer represents a distinct molecular subtype of the disease. Identifying this subtype through appropriate molecular testing enables oncologists to consider therapies specifically designed to inhibit ALK-related signalling pathways.
Ensartinib acts by targeting ALK activity, helping interfere with molecular signals that support the growth and proliferation of cancer cells.
The medicine is intended for a defined group of adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor.
Its use requires appropriate medical evaluation and confirmation of the relevant molecular characteristics of the cancer.
Medicine Already Approved in the United States and China
Ensartinib has received regulatory approval from the US FDA and China’s NMPA for specified indications involving ALK-positive non-small cell lung cancer.
These approvals establish the medicine’s regulatory status in the respective markets and provide the basis for its authorised use under the conditions specified by those regulators.
The approval of targeted oncology medicines involves the evaluation of clinical evidence concerning their efficacy, safety and appropriate use in defined patient populations.
For Ensartinib, the relevant indication concerns patients with ALK-positive lung cancer, a form of the disease in which molecular testing plays an important role in treatment selection.
The regulatory approvals in the United States and China do not automatically authorise the medicine’s sale in India. Mankind Pharma will need to complete applicable regulatory procedures before the product can be introduced into the domestic market.
Mankind Pharma Expands Its Oncology Portfolio
The agreement forms part of Mankind Pharma’s strategy to develop a more specialised pharmaceutical portfolio through a combination of internal capabilities and partnerships with international pharmaceutical innovators.
The company has been expanding its presence in specialised therapies, including oncology, while maintaining its established operations in the Indian pharmaceutical market.
The addition of Ensartinib provides Mankind Pharma with licensing rights to a patented targeted cancer medicine, extending its involvement in therapeutic areas that require specialised development, regulatory expertise and commercial capabilities.
The partnership also reflects the increasing importance of international licensing arrangements in pharmaceutical development, particularly where companies seek to introduce innovative medicines into additional geographic markets.
Such agreements allow pharmaceutical companies to combine the research capabilities of drug developers with the manufacturing, regulatory and commercial expertise of local partners.
Mankind Pharma Highlights Strategic Importance of Partnership
Atish Majumdar, Senior President of Mankind Pharma, described the agreement as an important development in the company’s strategy to build a differentiated oncology portfolio.
He stated that the in-licensing of Ensartinib strengthens Mankind Pharma’s focus on specialised therapies and supports its efforts to develop partnerships that complement the company’s existing capabilities.
Majumdar also highlighted the opportunity to expand Mankind Pharma’s presence in oncology and strengthen its ability to introduce advanced treatment options for patients in India.
The company’s approach combines domestic pharmaceutical capabilities with international collaborations intended to support the development and commercialisation of innovative medicines.
Betta Pharmaceuticals Seeks Wider Reach for Ensartinib
Betta Pharmaceuticals has identified the agreement as an opportunity to expand the reach of Ensartinib through cooperation with an established Indian pharmaceutical company.
Shizhe Ding, Chairman Assistant and Head of Business Development at Betta Pharmaceuticals, highlighted the importance of targeted treatment for patients with ALK-positive non-small cell lung cancer.
He stated that the partnership combines complementary capabilities and reflects a shared commitment to expanding therapeutic options for patients.
Betta Pharmaceuticals also expressed its intention to use the collaboration to support wider international access to the medicine and further explore its clinical potential.
The agreement represents a commercial partnership between an Indian pharmaceutical company and an international developer of targeted oncology therapies.
Targeted Cancer Therapies and India’s Pharmaceutical Industry
The development of targeted cancer therapies has introduced new approaches to treating cancers characterised by specific genetic or molecular abnormalities.
Unlike conventional treatments that act broadly on rapidly dividing cells, targeted therapies are designed to interfere with particular molecules or signalling pathways involved in cancer growth.
Molecular testing is therefore an important component of treatment selection for medicines such as Ensartinib, as their use depends on identifying patients whose cancers possess the relevant biological characteristics.
For India’s pharmaceutical industry, partnerships involving such medicines represent opportunities to expand into specialised therapeutic segments requiring advanced scientific, clinical and regulatory capabilities.
The Mankind Pharma–Betta Pharmaceuticals agreement reflects this approach by combining access to a patented oncology medicine with an established Indian company’s pharmaceutical development and commercial operations.
Strengthening Access to Specialised Cancer Medicines in India
The exclusive licensing agreement for Ensartinib marks another step in Mankind Pharma’s expansion into innovative oncology treatments.
Through the partnership with Betta Pharmaceuticals, the company has secured rights to pursue the development, manufacturing, registration and commercialisation of a targeted medicine for ALK-positive non-small cell lung cancer in India.
The medicine’s existing regulatory approvals in the United States and China provide an established international regulatory background, while its introduction into India will depend on the completion of applicable domestic approval and commercialisation requirements.
The agreement strengthens Mankind Pharma’s specialised pharmaceutical portfolio and provides a framework for bringing another targeted cancer therapy into the Indian healthcare market. It also illustrates the expanding participation of Indian pharmaceutical companies in international collaborations involving advanced medicines and molecularly targeted treatments.
You may also like
-
DG Propulsion Successfully Tests Automatic Relight Capability of Indigenous J100 Turbojet Engine
-
IISc-Incubated Thinking Balloon Successfully Tests Autonomous Tethered Aerostat Near Bengaluru
-
CUMI’s Indigenous Ceramic Vehicle Armour Achieves NATO STANAG Level 4 Qualification
-
Hathor Rockets Plans ₹250 Crore Rocket Engine Manufacturing and Testing Facility in Andhra Pradesh
-
Lupin’s Ranluspec Biosimilar Launched Across Europe Through Sandoz Partnership